Draupnir
Copenhagen, DK · Founded 2017 · 19 employees on LinkedIn · 4 known investors
Find your way into Draupnir
Draupnir Bio develops targeted protein degradation therapies using sortilin-based lysosome targeting chimeras to clear extracellular and membrane-bound protein aggregates in proteinopathies. The company, a spin-out from Aarhus University and Max-Planck Society, builds proprietary platform technology to treat diseases with significant unmet medical need.
Founders & leadership
Draupnir was founded in 2017 by Simon Glerup, Camilla Gustafsen, Peder Søndergaard Madsen, and Peter Seeberger.
Investors · 4
In the news
Frequently asked questions
- What does Draupnir do?
- Draupnir Bio develops targeted protein degradation therapies using sortilin-based lysosome targeting chimeras to clear extracellular and membrane-bound protein aggregates in proteinopathies. The company, a spin-out from Aarhus University and Max-Planck Society, builds proprietary platform technology to treat diseases with significant unmet medical need.
- Who founded Draupnir?
- Draupnir was founded by Simon Glerup, Camilla Gustafsen, Peder Søndergaard Madsen, Peter Seeberger in 2017.
- Who are Draupnir's investors?
- Draupnir's investors include Gilde Healthcare, Inkef, MC Healthcare Ventures, Novo Holdings.
- Where is Draupnir headquartered?
- Draupnir is headquartered in Copenhagen, DK.